Full-Time
Automated platform for live single-cell assays
$120k - $170k/yr
Foster City, CA, USA + 1 more
More locations: San Diego, CA, USA
In Person
Travel up to 50% of working time, including occasional overnight and weekend travel.
Bachelor's, Master's
See people who can refer or advise you
Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.
Company Size
51-200
Company Stage
Series C
Total Funding
$276.9M
Headquarters
Foster City, California
Founded
2020
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Stock Options
401(k) Retirement Plan
Flexible Work Hours
EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-588010 | Film No.: 261104659
Cellanome has filed a notice with the US Securities and Exchange Commission to raise up to $75.9 million in new funding. The filing was made under Regulation D of the Securities Act of 1933, which allows companies to sell securities without full registration. The company develops technologies that combine longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This approach enables scientists to capture cellular dynamics over time and connect cellular behaviour with molecular state. Researchers can access Cellanome's technology by implementing its R3200 platform in their laboratories, using its assay services, or collaborating with the company's scientists on new applications.
A Peninsula startup launched by top former Illumina execs raises $150 million to help researchers see what happens when cells dance with each other.
Biotech A-listers have come together to launch a new venture. What's it targeting? They're not saying.